BTIG Research's Dane Leone initiated coverage on a cancer treatment and infectious disease biotech company Thursday afternoon, MacroGenics Inc MGNX.
The analyst set a Buy rating and $35 price target, representing potential upside of about 63 percent from the stock's close.
Leone said MacroGenics is a "must-own" stock at current levels, considering the company's "discount on bi-specific platform plus enoblituzumab data."
Even with the company's clinical catalysts being largely back-end loaded this year, he iterated valuation offers "attractive opportunity on the long side for three key reasons:
- The substantial stock discount of the current enterprise value when compared to the potential payments from multiple partnerships across the DART platform,
- Presentation of the Enoblituzumab Phase I data during late 2016 should help bridge news flow into Margetuximab updates during 1H2017, and
- Our NPV analysis of current clinical programs could significantly increase as the B7-H3 data warrants incorporation of Enoblituzumab and/or MGD009."
Shares of MacroGenics closed Thursday at $20.32, down 5.1 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.